Videos

Early RENEW-HD data support moving the 13 kg Neokidney to autonomous use testing, with dialysate calcium adjustments planned.

Jean Bourbeau, MD, says AI analysis of CT scans is not ready for routine use but could reshape early COPD diagnosis as GOLD expands its AI guidance.

Hugh Gallagher, MBBS, PhD, discusses a 27% lower point estimate for cardiovascular events with aspirin that was not significant.

Sarina Berger Elmariah, MD, PhD, MPH, reviews 3-year nemolizumab data showing deeper skin clearance and lasting itch relief in atopic dermatitis responders.

In a randomized crossover trial, a liberalized produce diet raised urinary potassium excretion without changing serum potassium.

Rajiv Agarwal, MD, MS, explains why decades of pentoxifylline data in DKD remain inconclusive and how the VA PTXRx trial aims to settle the question.

Roshen Mathew, MD, DAABIP, discusses STABLE, in which diagnostic yield was 86.8% with breath-hold vs 92.2% with conventional ventilation.

Todd Schlesinger, MD, reviews new photodynamic and adjuvant immunotherapy options for keratinocyte carcinoma, plus pipeline therapies and exosome research.

Chance, biology, and shared genetics may explain more small for gestational age births after living kidney donation.

A Canadian cohort found modestly greater preeclampsia risk after donation, though most pregnancies were uncomplicated.

Phoom Narongkiatikhun, MD, discusses sleeve gastrectomy reducing LV mass, kidney volume, and albuminuria and boosting medullary FSOC in youth-onset T2D.

In the MEnD-AKI trial, pharmacists reviewed deep learning predictions of AKI risk across 38 hospital service clusters at 8 hospitals.

In the MEnD-AKI trial, pharmacists reviewed deep learning predictions of AKI risk across 38 hospital service clusters at 8 hospitals.

Calcified vessels may mask PAD on ankle brachial index testing, and Garimella says nephrologists can help catch it earlier.

Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.

Amit X. Garg, MD, PhD, discusses new JAMA data on preeclampsia risk after living kidney donation in a 3-part video interview.

Fabiano Cavalcante, MD, discusses his secondary analysis of the DISTAL trial, which revealed minimal association between IVT and the effect of EVT in MDVO strokes.

Amy Yu, MD, MSc, discusses her presentation at WSC 2026 discussing highlighting the present danger of this underrepresented disease state.

Michael Wechsler, MD, reports 59% of patients in clinical remission with twice-yearly depemokimab at year 1 maintained it at year 2 in SWIFT/AGILE.

Frank Sciurba, MD, reports tozorakimab improved E-RS:COPD scores vs placebo at week 52 in OBERON and TITANIA, including breathlessness and chest symptoms.

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

From false positives to lost follow-up and unneeded LTBI therapy, experts detail the harms of routine TB testing with IL-17 and IL-23 inhibitors in psoriasis.

The NPF/IPC TB statement isn’t a blanket no-test rule. Experts explain when screening still fits, from endemic regions to JAK inhibitors and other DMARDs.

Experts explain why ustekinumab and TYK2 inhibitors were excluded from new TB testing guidance and how FDA label changes for IL-17/IL-23 agents could happen.

Basic science, trials, real-world data, and FAERS reports show little TB reactivation risk with IL-17 and IL-23 inhibitors, supporting new NPF/IPC guidance.

New NPF/IPC guidance questions routine TB testing for IL-17 and IL-23 inhibitors in psoriasis, a TNF-era practice lacking direct supporting evidence.